Through this program, the investigational drug MK-3475 will be provided to patients with metastatic melanoma who have tried other treatments and who have few or no other treatment options. In prior studies of patients with advanced melanoma, some patients who received MK-3475 experienced tumor shrinkage and cancer control for a long period of time.
MK-3475 is a protein called an antibody which binds to PD-1, a protein on T cells (a type of white blood cell). It is hoped that when MK-3475 binds to PD-1, it will “turn on” the T cells and cause the immune system to detect and destroy cancer cells. MK-3475 is given intravenously (by vein).